Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Rheumatol Int ; 37(10): 1687-1691, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28831595

RESUMEN

Juvenile systemic sclerosis (JSSc) is a rare disorder with paucity of information on its treatment and longterm  outcome. Herein, we are sharing our experience with this rare entity. Case records of children, diagnosed to have systemic sclerosis attending Pediatric Rheumatology Clinic at All India Institute of Medical Sciences, New Delhi from January 1998 to June 2016 were reviewed. The demographic, clinical, laboratory, treatment and outcome details were recorded. Disease outcome was classified arbitrarily as controlled, partly controlled or non-responsive/progressive based on: (A) ability to perform activities of daily life (ADL) and (B) presence or absence of musculoskeletal symptoms, skin changes (ulceration/progressive digital pitting/gangrene), and visceral organ involvement (dyspahgia, cardiopulmonary symptoms). Controlled: ability to perform ADL and absence of B features for at least 6 months. Partly controlled: inability to perform ADL or any of the B features. Non-responsive/progressive disease: presence of both A and any of B features. Thirty-two children (21, girls) diagnosed as systemic sclerosis for whom follow-up of more than 6 months was available were included for this retrospective analysis. Mean (SD) age at presentation was 112.79 (30.05) months, while the median (IQR) delay in diagnosis was 28.5 (9-47.25) months. Of the 32 children 17 (53.12%) had diffuse systemic sclerosis (dSSc), 5 (15.62%) had limited systemic sclerosis (lSSc) and 10 (31.25%) had sclerosis with overlap syndrome. The common clinical features apart from sclerosis/induration proximal to metacarpophalangeal joint were Raynauds phenomenon (n = 22, 68.7%), skin rash (n = 20, 62%), arthritis or arthralgia (n = 16, 50%), and muscular weakness (n = 10, 31.2%). Among those for whom data regarding investigations were available; ANA was positive in 50% (12/24), whereas Anti Scl70 was positive in one out three cases. Treatment regimen included naproxen, methotrexate, calcium channel blockers with or without steroids. HCQ was added in children with skin rash or in children with partial control. Median (IQR) follow-up period was 19.75 (12-31.75) months. With the above treatment protocol, 19 (59.3%) children achieved disease control on treatment, 8 (26.6%) had partial control while 5 (16.6%) showed no response or progressive disease. Esophageal dysmotility and intertitial lung disease (ILD) were documented in three children each. Complication (cataract and herpes zoster) related to immunosuppressive therapy were observed in two children. There was no mortality during the study period. Juvenile Sclerosis though rare is associated with significant morbidities and lacks a curative treatment but a reasonable quality of life to perform daily activities can be achieved using methotrexate and steroid-based immuosuppressive therapy.


Asunto(s)
Antiinflamatorios/uso terapéutico , Artralgia/etiología , Artritis/etiología , Inmunosupresores/uso terapéutico , Enfermedad de Raynaud/etiología , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/tratamiento farmacológico , Actividades Cotidianas , Adolescente , Bloqueadores de los Canales de Calcio/uso terapéutico , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Humanos , India , Masculino , Calidad de Vida , Estudios Retrospectivos , Esclerodermia Sistémica/complicaciones , Centros de Atención Terciaria , Resultado del Tratamiento
2.
Trop Doct ; 47(4): 336-339, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28409532

RESUMEN

The gold standard for detecting bacterial sepsis is blood culture. However, the sensitivity of blood culture is low and the results take 48-72 h. Molecular assays for the detection of bacterial DNA permit early detection of a bacterial cause as the turnaround time is 6-8 h. We undertook an evaluation of the performance of universal bacterial primer (16S rRNA) polymerase chain reaction (PCR) in the diagnosis of neonatal sepsis at a tertiary care medical college teaching hospital. 16S rRNA PCR was positive in all cases of blood culture proven sepsis. PCR revealed 95.6% sensitivity, 100% specificity, 100% positive predictive value and 91.2% negative predictive value and so appears to be a useful tool for the early diagnosis of bacterial neonatal sepsis.


Asunto(s)
Bacterias/aislamiento & purificación , Sangre/microbiología , ADN Bacteriano/genética , Sepsis Neonatal/diagnóstico , ARN Ribosómico 16S/genética , Bacterias/genética , Técnicas Bacteriológicas , Peso al Nacer , Países en Desarrollo , Reacciones Falso Positivas , Femenino , Edad Gestacional , Humanos , India , Recién Nacido , Masculino , Sepsis Neonatal/sangre , Sepsis Neonatal/microbiología , Reacción en Cadena de la Polimerasa/métodos , Valor Predictivo de las Pruebas , Sensibilidad y Especificidad
3.
Trop Doct ; 46(3): 142-8, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26612093

RESUMEN

OBJECTIVE: To evaluate clinically the efficacy and safety in northern India of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia. MATERIAL AND METHODS: Children aged ≤18 years admitted febrile with chemotherapy-induced neutropenia were randomised into two groups comprising 20 cases in each group viz. CEF (receiving cefepime only) and PIP-TAZO (receiving piperacillin-tazobactam). Based on clinical and laboratory tests, patients were classified into: microbiologically documented infections (MDI); clinically documented infections (CDI); and unexplained fever (UF). They were assessed for clinical signs and symptoms as well as laboratory parameters at the time of enrolment and subsequently on days 3 and 7. RESULTS: Incidence of MDI, CDI and UF were 22.5%, 47.5% and 30%, respectively. The mean duration of neutropenia (in days) was 5.45 ± 2.1 in the PIP-TAZO group and 5.5 ± 1.5 in the CEF group (P = 0.305). The success rate defined as clearing infection effectively and improvement of neutropenia was comparable (P = 0.705). There was a mortality rate of 20% in the PIP-TAZO group as compared to 10% in the CEF group. CONCLUSION: We conclude that cefepime monotherapy and piperacillin-tazobactam are equally efficacious and safe in treating patients with febrile neutropenia. Empirical monotherapy with cefepime would prevent an unnecessary extra economic burden as well as avoiding the serious adverse or toxic effects of multi-drug regimes, especially in low- and middle-income countries.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Cefalosporinas/uso terapéutico , Neutropenia Febril/tratamiento farmacológico , Ácido Penicilánico/análogos & derivados , Adolescente , Infecciones Bacterianas/complicaciones , Cefepima , Niño , Preescolar , Quimioterapia Combinada , Neutropenia Febril/inducido químicamente , Femenino , Fiebre/etiología , Humanos , India , Masculino , Ácido Penicilánico/uso terapéutico , Piperacilina/uso terapéutico , Combinación Piperacilina y Tazobactam , Estudios Prospectivos , Centros de Atención Terciaria , Resultado del Tratamiento
4.
J Clin Diagn Res ; 9(4): SD04-5, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26023615

RESUMEN

We describe a case of a large simple neonatal ovarian cyst, which was managed successfully using "wait and watch" approach and serial ultrasound monitoring. A cystic lesion arising from right ovary was noted in antenatal ultrasound (USG) which was followed up with postnatal USG which revealed a large simple ovarian cyst without any complications. Patient was kept on expectant management with close clinical and USG monitoring. Cyst resolved spontaneously at 10 wk of age. A brief review of literature for likely aetio-pathogenesis and management is also presented.

SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda